Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Cantor Presentation (June 2021)
17 slides from Zelira Therapeutics's conference presentation, Jun 29, 2021
Slide 1: A Global Biopharmaceutical Company Developing and Marketing Clinically Validated Cannabis Medicines
A Global Biopharmaceutical Company Developing and ASX: ZLD OTCQB: ZLDAF Marketing Clinically Validated Cannabis Medicines WWW.ZELIRATX.COM 1
Slide 2: Disclaimer & Important Notice
Disclaimer & Important Notice Disclaimer Future Matters This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 (“Company”). It does not This presentation contains reference to certain intentions, expectations, future plans, purport to contain all the information that a prospe
Slide 3: Company Overview
Company Overview Zelira is a global biopharmaceutical Global Markets Strategy Fast Tracking Commercialization company developing, and marketing US, Australia, UK and EU footprint to rapidly Disruptive ‘Launch, Learn, & Develop’ model access the largest, most profitable & fastest facilitates rapid co
Slide 4: Zelira Revenue Streams
Zelira Revenue Streams 01 02 03 Launch & Learn Oral Health Dermatology Rx OTC OTC Autism Toothpaste Five Products- Aged disorders Additional Products- 2H,2021 launch 2H, 2021 Launch 04 05 Clinical Trials Pharma Rx Rx Insomnia Pain Opioid Sparing GI Autism 4 Confidential under terms of non-disclosure
Slide 5: Rapid Commercialisation Strategy
Launch, Learn & Develop Rapid Commercialisation Develop Strategy • Patient data informs and de-risks design of clinical trial • 43% costs reimbursable via Australian R&D rebate program • Supports path to registration Learn • Collect real-world patient data • Refine product to meet patient needs • Re
Slide 6: Global Market Opportunities
Global Market Opportunities Australia 25M 11K 30-50K $150M 2019 population Registered medical Forecast patient numbers Market sales: 20201 cannabis patients1 end of 20201 (Growth rate: 400% ) Germany 83M 65K 90% $195M 2019 population Registered medical Population covered by Market sales:20193 cannab
Slide 7: Rich Product Pipeline
Rich Product Pipeline Product Launch Market HOPE for Autism Launched 2020 2020 2021 Insomnia (Zenivol®) Launched 2020 2020 2021 Oral Care (SprinjeneCBD) Launched 2021 2020 Additional Products 2H 2021 Dermatology ( 5 products) Launches 2021 2H 2021 Targeted Pain Launches 2021 2H 2021 Aged Disorder La
Slide 8: HOPE for Autism - Rx
HOPE™ for Autism - Rx Overview HOPE developed with and for the Autism community Published Real life data report-HOPE™ improves autism-related symptoms and quality of life for survey participants US Revenues: Licensed in Louisiana and Washington DC (Deal Structure: Upfronts + double digit royalty). M
Slide 9: Zenivol for Insomnia - Rx
Zenivol®-For Insomnia - Rx Overview • World’s first clinically validated cannabinoid drug for chronic insomnia • Phase 1B/2A clinical trial confirmed Zenivol® safe, efficacious and improved quality of life • Significant reduction in insomnia symptoms • Clinical trial results published in peer review
Slide 10: Oral Care - Sprinjene CBD - OTC
Oral Care –Sprinjene CBD - OTC Overview Product for full line of CBD oral care products Toothpaste was launched in Q1 2021 and generating revenue with strong growth potential. Available for purchase on zeliraoralcare.com, sprinjenecbd.com, amazon.com and wholesale distribution channels in the US Exp
Slide 11: Differentiated Dermatology - OTC
Differentiated Dermatology- OTC Overview Science-backed Platform ZylormaTM , a proprietary, patent pending, acne fighting complex with CBD, Salicylic acid and additional compounds to fight bacteria and clogged pores associated with acne , Technology balance sebum production to help eliminate & preve
Slide 12: RAF FIVE Products Launch
RAF FIVE™ PRODUCTS LAUNCH 12 Confidential under terms of non-disclosure agreement
Slide 13: RAF Five product range
WASH AWAY GEL CLEANSER ACNE TREATMENT AFTER HOURS MOISTURIZING LOTION ACNE TREATMENT WASH UP ACNE CLEANSER CLEAR THE WAY ACNE TREATMENT PADS KICK OFF HYDRATING LOTION BROAD SPECTRUM SPF 30 SUNSCREEN 13
Slide 14: Recent Milestones
Recent Milestones 01 Treating Insomnia Symptoms with Medicinal Zenivol® clinical trial results published in the prestigious Cannabis: A Randomized, Cross-Over Trial of the Read peer-reviewed journal SLEEP® Efficacy of a Cannabinoid Medicine Compared with Placebo 02 Clinical Pain Trial with Retired P
Slide 15: Corporate Snapshot
Corporate Snapshot Financials (as at March 30 2021) Share Price (as at March 30 2021) AUD$ Share Price $0.060 52w Range $0.041 - 0.140 Market Capitalisation 72.8m Cash (March 2021) $6.5m Capital Structure (Fully Diluted2) Structure Major Shareholders Directors Holdings: 37% Ilera Investors 44% Top 2
Slide 16: Global Board of Directors & Management
Global Board of Directors & Management Global Dr. Oludare Odumosu: CEO & Managing Director • Post-clinical development of Iroko Pharmaceutical’s Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization. • Founding COO of Ilera Healthcare. Ilera healthcare wa
Slide 17: Thank You
Thank You Zelira Therapeutics +1-484-630-0650 zeliratx.com info@zeliratx.com A Global Biopharmaceutical Company Developing and Marketing Clinically Validated Cannabis Medicines 17
Zelira Therapeutics — Cantor Presentation (June 2021) on 6ix